Access to Medicine Index 2022 ▶ Company report cards

RA N KSCO R E2

4.03

3 (2021)

Johnson & Johnson
Stock exchange: NYSE • Ticker: JNJ • HQ: New Brunswick, New Jersey, USA • Employees: 141,700

PERFORMANCE IN THE 2022 INDEX
2nd place. Johnson & Johnson is a leading company anddemonstrates strong performance across all three Technical
Areas. The company performs strongly across all assessment
criteria including access strategies, R&D access planning and

How score was achieved
4.43

Governance of Access
3.73

Research & Development

4.09

Product Delivery

capacity building.

0

1

Governance of Access: 2nd place. Johnson & Johnson has

2

3

Average

Leader4

5

a strong performance in this area. It has an access-to-medicine strategy integrated into its overall corporate strategy and a robust set of compliance controls to mitigate thein R&D capacity building and has an access planning frame-risk of non-compliance in countries in scope of the Index. It

work that covers all projects in the pipeline.

also incentivises its senior executives, the CEO and in-country and regional managers to perform on access-to-medicine

Product Delivery: 3rd place. Johnson & Johnson performs

goals and discloses the outcomes of its access-to-medicine

strongly in this area. The company engages in high-qual-

activities.

ity capacity building initiatives across all fields (i.e., manufacturing, supply chain and health systems strengthening). The

Research & Development: 2nd place. Johnson & Johnson is acompany applies access strategies broadly, with several prod-

leading company in this area. The company has a large-sized

ucts having strategies across all country income classifica-priority pipeline compared its peers with access plans in placetions. It leads in its approach to access strategies for suprana-

for all late-stage pipeline candidates. It also performs strongly

tionally procured products.

OPPORTUNITIES FOR JOHNSON & JOHNSONCHANGES SINCE THE 2021 INDEX

Improve the quality of access plans for R&D projects for non-communicable diseases.

• Expanded the scope of its Global Public Health organisation

Johnson & Johnson has access plans in place for all its late-stage R&D projects inthe pipeline. The company can plan beyond registration by including more accesscomponents such as equitable pricing plans for each project, including cetrelimab,a monoclonal antibody in development for bladder cancer, and aprocitentan, an

to include a focus on Global Surgery, including obstetricfistula.
• Launched new Health for Humanity 2025 Goals, including agoal on Global Access Plans.

investigational treatment for hypertension.

• Shipped approximately 270 million doses of the Johnson &Expand supply chain process reviews to more countries. Johnson & Johnson’s• Entered into IP licensing agreements and conducted

Johnson COVID-19 vaccine to Africa at a not-for-profit price.
Global Public Health unit conducted supply chain process reviews in sub-Saharan

voluntary technology transfers for its COVID-19 vaccine

African countries including Kenya, Uganda and Nigeria. These reviews revealed a gap

across 10 manufacturing facilities, including in India andin leadership skills in the supply chain. In response, the company launched the PublicSouth Africa.

Health Supply Chain CEO Forum. The company can conduct needs assessments in• Announced an agreement to provide its COVID-19 vaccine

further countries in sub-Saharan Africa and expand the forum to additional countries

technology to South Africa-based Aspen SA Operations

where supply chain leadership gaps are seen.

(Pty) Ltd to manufacture its own branded vaccine.
• Received WHO Prequalification for its Ebola vaccine (Ad26.

File patented medicines for HIV for registration in more countries. Johnson &ZEBOV-GP) (Zabdeno®) and Ebola vaccine (MVA-BN-Filo)Johnson’s antiretrovirals darunavir/cobicistat (Prezcobix®/Rezolsta®) and darunavir/
cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) have been filed in 12 and 5
countries in scope of the Index respectively. Both products can be filed for registrationin countries with a high burden of disease, such as Mozambique, South Africa and(Mvabea®)• Announced several initiatives to help find the ‘Missing
Millions’ of undiagnosed people living with TB, including
with the Global Fund.

Zimbabwe.

• Launched a network of Global Health Discovery Centers to

Expand access to patented products in countries with the highest burden of disease.

• Completed Phase 1 clinical study evaluating dengue-specificaccelerate innovation and tackle pandemic threats.
Johnson & Johnson has access strategies in some LMICs for canagliflozin (Invokana®),
indicated for type 2 diabetes mellitus, and for ibrutinib (Imbruvica®), indicated forleukaemia. The company can apply access strategies such as equitable pricing and/or
non-exclusive voluntary licensing to expand patient reach, particularly in countries inscope of the Index where the burden of disease is the highest, such as Sri Lanka (fordiabetes) and Afghanistan (for leukaemia).

antiviral for treatment and prophylactic use.
• Invested USD 100 million into the newly launched
Antimicrobial Resistance (AMR) Action Fund.
• Commenced the first interventional clinical trial for
schizophrenia in Africa.
• Marked over 2 billion doses of mebendazole (Vermox®)
donated since 2006.

45

All companies were assessed based on
information that was valid in the latest
period of analysis (ending at 31 May2022). This data was either submitted bycompanies, found in the public domain or
was accessible through other sources.

The term LMICs is used to denote all
low- and middle-income countries inscope of the Index, except when analysing
companies’ access strategies where
the use of LMIC refers to lower-middle
income countries as per the World Bank

income groups classification. Likewise, theterms LIC and UMIC refer to low income
countries and upper-middle income
countries.

Access to Medicine Index 2022 ▶ Company report cards

SALES AND OPERATIONSBusiness segments: Consumer health, medical

M&A news: Johnson & Johnson acquired

technologies and pharmaceutical.

Momenta Pharmaceuticals, Inc. in October 2020

Sales by segment (2021) – in USD

Therapeutic areas: Cardiovascular, immunology,

for USD 6.5 billion.

infectious diseases, metabolism, neuroscience,

Consumer health

14.64 bn

Pharmaceutical

52.08 bn
27.06 bnoncology, pulmonary hypertension and otherJohnson & Johnson's products are sold in 95

Medical technologies

diseases.

out of 108 countries in scope of the Index.

		Product categories: Consumer health products,

Johnson & Johnson has sales offices in 24

Total

innovative medicines, medical technologies andcountries and sells via suppliers and/or pooled

vaccines.

procurement in an additional 71 countries.

Sales by geographic region
100

Sales (Bn USD)

Sales in countries in scope

93.78 bn

80
60
40
20
0

In scope, has sales offices
In scope, any sales

2017
USA

In scope, no sales

2018

2019

2020

2021

International

Not in scope

SAMPLE OF PIPELINE AND PORTFOLIO ASSESSED BY THE INDEXPIPELINE for diseases in scope

PORTFOLIO as selected for analysis by the Index

Johnson & Johnson has a total of 101 R&D projects in scope with 64 ofJohnson & Johnson has 26 medicines in scope, 19 of which are on patent,these projects targeting priority diseases. The other 37 R&D projects tar-and two vaccines. 42% of the medicines (11) are on the WHO EML. The

get other diseases in scope. Of the projects targeting priority diseases, theoff-patent medicines target the neglected tropical diseases soil-transmit-

focus is on viral hepatitis (B and C) (12 projects), HIV/AIDS (11 projects), andted helminthiasis and echinococcosis and the non-communicable diseases

tuberculosis (11 projects). Of the projects targeting other diseases in scope,(NCDs) (6) relating to cancer (3), mental health conditions (2) and kidney

the focus is on oncology (25). Forty R&D projects are in late-stage develop-

diseases. The on-patent medicines target communicable diseases such as

ment. These target either a priority disease (19) or address a public health

HIV/AIDS (8) and tuberculosis, and NCDs such as cancer (5), mental healthneed in LMICs (21).* Evidence of access planning was in place for 100% ofconditions (2), diabetes (2) and Alzheimer's disease. The company also hasthese projects.

two vaccines targeting Ebola and COVID-19.

101 projects in the pipeline

28 products as selected for analysis by the Index†
55

Communicable**

Maternal and neonatal 036

Non-communicable16

Non-communicableMultiple categories 0Multiple categories 0
0

40
60
80
100
projects in the pipeline

20
30
40
50
products on the market

Other***

5

3 64

13

5

2

7

Vaccines

0

2

2

Contraceptives

00Addresses needs of LMICs*

4

7

13

1

0 25

Diagnostics

Other projects in scope

9

2

1

0

0 12

Other

*50 diseases and 243 product gaps inscope have been established as a priority by global health stakeholders. For
other diseases, the Index used a set of criteria to determine which projects in thepipeline offer a clear public health benefit to patients in LMICs. Only projects inthe clinical phase of development were
included for this analysis.
**Neglected tropical diseases, while also
communicable, are highlighted separately
throughout the Index.
***Other includes projects that have atechnical lifecycle and projects that fol-

‡

Total

Registration/approval

7

6

off patent

Other

Phase III8

Medicines on patent

WHO EDL

Phase II

9

Non-EML

Phase I

23 9

Total

Pre-clinical

Breakdown of products

Discovery

Targets established R&D priorities

10

WHO EML

20

Breakdown of projects

46

1

Neglected tropical

Maternal and neonatal 1

0

11Communicable**

9

Neglected tropical

19

0
0

0
0

low a different development cycle (e.g.
diagnostics).
†Products included in the analysis wereselected using a set of criteria determinedby stakeholder consensus.
‡Other includes vector control products.

0

Access to Medicine Index 2022 ▶ Company report cards

Johnson & Johnson

GOVERNANCE OF ACCESSRANK 2SCORE 4.43

Has an access-to-medicine strategy with meas-in scope of the Index. It facilitates accountabil-

try risk-based assessment, a continuous systemurable objectives, integrated within its overall

ity and transparency by consistently sharing theto monitor activities, audits (both internal andcorporate strategy. Johnson & Johnsons per-outcomes of its access-to-medicine activities inexternal, covering third parties and in all coun-forms strongly. Its access strategy, embedded ina centralised manner within its annual Health fortries where it operates) and has formal processes

its Global Public Health unit and Janssen Access

Humanity Goals Progress Scorecard.

to ensure third-party compliance with company

and Pricing Principles, covers all therapeutic

standards. No breaches in countries in scope ofareas in which the company is involved. The high-

Performs above average in responsible pro-the Index were publicly found in the period of

est responsibility for access lies directly with the

motional practices. Johnson & Johnson’s sales

analysis.

board, namely with the Science & Technology

agents are not solely incentivised on sales volume

Committee.

targets. The company, however, sets sales incen-

Publicly supports international agreements,

tives at the individual level for agents. It does not

such as the Doha Declaration on the TRIPS

Provides evidence of financial and non-financial

publicly disclose information related to transfers

agreement. Johnson & Johnson publicly rec-access-related incentives at the executive level.

of values to healthcare professionals in countries

ognises and supports international agreements

Johnson & Johnson performs strongly. It incen-

in scope of the Index (e.g. payments for attend-

including the TRIPS Agreement, and states thattivises its senior executives, including its CEO

ing events or promotional activities) except as

it advocates for strong intellectual property (IP)and members of the Executive Committee, andrequired by law or national/regional trade asso-

systems that promote innovation. The company

regional managers to take action on access tociations (e.g., EFPIA), though it has policies andexpresses reservations on compulsory licensing,

medicine with financial and non-financial rewards.

procedures in place limiting transfers of values tonamely that it should be limited to certain circum-

Senior management, including the CEO, have

healthcare professionals in countries in scope ofstances when alternatives are exhausted. There

enterprise-level targets as well as access-related

the Index. In addition, the company reports not

is evidence of industry association lobbying on

performance indicators, including KPIs to improveusing sales and marketing representatives for

IP and the usage of TRIPS flexibilities, namely

access to medicine, as part of their annual goals

some products related to diseases in scope, suchof compulsory licensing, by national govern-and objectives.

as HIV/AIDS medicines.

ments in some countries in scope of the Index. As

Publicly discloses outcomes of its

Has a robust set of compliance controls to& Johnson, like all other member companies inaccess-to-medicine activities. Johnson &ensure that governance efforts are not under-

scope of the Index, is by default connected to thisJohnson performs strongly in transparency of

mined by non-compliant or corrupt activities.

activity.

access activities. It publicly discloses commit-

Johnson & Johnson performs strongly, demon-

ments, measurable goals, objectives and targets

strating evidence of all components looked for by

for improving access to medicine in countries

the Index: fraud-specific risk assessment, coun-a member of the industry association, Johnson

RESEARCH & DEVELOPMENTRANK 2SCORE 3.73

Access planning processes encompass all pro-range of components including equitable pricing

first-in-class molecules. The projects mainly target

jects in the pipeline. Johnson & Johnson has

strategies and plans for registration in countries

cancer. Johnson & Johnson provides evidence ofa structured process in place to develop accessin scope of the Index. Notably, the access plan

access plans for all 21 eligible projects.

plans during R&D. The process is intended to be

for the two-shot regimen Ebola vaccine (Ad26.

applied to all R&D projects (both in-house and

ZEBOV-GP) (Zabdeno®) and Ebola vaccine (MVA-

Does not publicly disclose R&D investment

collaborative) for diseases in scope of the Index.

BN-Filo) (Mvabea®) is multifaceted, comprising ofdata disaggregated by disease category, prod-

In general, Johnson & Johnson begins developing

WHO prequalification, health systems strength-

uct type or phase of development. However,access plans for R&D projects in Phase II of clini-ening and capacity building initiatives through theJohnson & Johnson does disclose fully disag-cal development.

Johnson & Johnson vaccination monitoring plat-gregated R&D investment data to Policy Cures

form Vxnaid™, and product donations.

Research.

to peers, with access plans in place for 100%Many projects address a public health need in

All five R&D capacity building initiatives included(19/19) of the late-stage candidates. Johnson

LMICs,* with 100% (21/21) of late-stage projects

for analysis meet all Good Practice Standards.

& Johnson has a priority R&D pipeline of 64 pro-covered by access plans. In this analysis, Johnson

Johnson & Johnson leads in this area. The number

jects, including 19 late-stage projects that target a& Johnson has 21 late-stage R&D projects thatof initiatives meeting all inclusion criteria is higher

priority gap. The company focuses on various pri-target a disease and/or product gap not yet estab-than average and more initiatives meet all Good

ority areas, including viral hepatitis (B and C), HIV/lished as a priority by global health stakeholders.

Practice Standards than what is average for thisAIDS and tuberculosis. Of Johnson & Johnson's

These projects are all deemed by the Index toindicator. For example, the Johnson & Johnson

19 late-stage candidates targeting a priority prod-offer a clear public health benefit for people living

Global Public Health R&D Fellowship Program pro-uct gap, all have evidence of an access plan in

in LMICs.* Primarily, these projects have clinical tri-

vides training in drug development to mid-career

place. It provides evidence of access plans with a

als in countries in scope of the Index and/or are

African doctors and scientists.

A large-sized priority R&D pipeline compared47*50 diseases and 243 product gaps inscope have been established as a priority
by global health stakeholders. For otherdiseases, the Index used a set of criteria
to determine which projects in the pipeline offer a clear public health benefit topatients in LMICs. Projects in the clinicalphase of development were included forthis analysis.

Access to Medicine Index 2022 ▶ Company report cards

PRODUCT DELIVERYRANK 3SCORE 4.09

Public commitment not to enforce patents inwith the African Vaccine Acquisition Trust (AVAT)

Standards. Johnson & Johnson is one of thecountries in scope. Johnson & Johnson has had

as well as two advance purchase agreements withleaders in this area. The number of initiatives

a specific policy since 2012 not to enforce thethe South African government.

meeting all inclusion criteria is higher than aver-patents it owns and controls on the antiretro-

age and more initiatives meet all Good Practiceviral drug darunavir (Prezista®) in sub-Saharan

Has access strategies for the majority ofStandards than what is average for this indicator.

Africa and Least Developed Countries. In 2015,

healthcare practitioner-administered products

For example, Johnson & Johnson Global Public

it expanded the geographical scope of the policyin scope of this analysis. Johnson & Johnson

Health developed Vxnaid™, a vaccination moni-for paediatric products used in LMICs.

performs above average in this area. For three of

toring platform which supports adherent vaccine

the five products assessed, the company provides

administration in the framework of clinical studies

Publicly discloses information on patent sta-examples of access strategies which consider

or campaigns, including support of the Rwandantus. Like most of its peers, Johnson & Johnson

affordability in countries of all assessed income

Ministry of Health’s large-scale Ebola vaccination

discloses the patent statuses for small mole-levels (UMIC, LMIC, LIC). The company makes

campaign. The company’s ultimate goal is for thecules in scope via the Pat-INFORMED database.

efforts to reach additional patients using strate-

platform to be available on a more global scale.

Johnson & Johnson discloses patent information

gies considering relevant payers' ability to pay. For

including filing date, grant number, grant date andexample, Johnson & Johnson secured bendamus-

Has engaged in scaling up two and piloting four

jurisdiction.

tine hydrochloride (Ribomustin®) reimbursement

inclusive business models. Johnson & Johnson

in both public institutions and private healthperforms above average in the use of inclusive

Performs above average in terms of sharing

insurance in Brazil. The company provides evi-business models aimed at meeting the accessintellectual property (IP) assets with third-

dence of how patient reach has been increased

needs of populations at the base of the income

party researchers. Johnson & Johnson engaged

through the approaches used in some of the

pyramid (including other underserved popu-

in two new IP-sharing agreements with third-

country examples provided.

lations) in LMICs. Johnson & Johnson Impact

party research institutions or drug discovery

Ventures, a fund within the Johnson & Johnson

initiatives established during the current analysis

Has access strategies for the majority of its

Foundation, helped to scale up South Lakeperiod that meet all inclusion criteria for evalua-self-administered products for countries in

Medical Center, a specialised low-cost primarytion. The company does have existing agreements

scope for this analysis. Johnson & Johnson per-care hospital in Naivasha, Kenya that runs a hub-of this nature in place that were establishedforms above average in this area. For two of theand-spoke healthcare model.

before the current Index cycle and meet all inclu-

five products assessed, the company provides

sion criteria for evaluation.

examples of access strategies which consider

Performs above average in terms of ensur-

affordability in countries of all assessed income

ing continuous supply of medicines in LMICs.

Uses licensing to enable generic supply.

levels (UMIC, LMIC, LIC). It makes efforts to reachJohnson & Johnson is involved in technology

Johnson & Johnson has a non-exclusive vol-additional patients through pricing strategies con-transfers with third-party manufacturers in LMICs,

untary licensing agreement for one compoundsidering relevant payers' ability to pay and patientand has a system in place to work with relevant(for diseases in scope). Its licence for rilpivirine

assistance programmes. For example, in an LIC

stakeholders to communicate issues that may(Edurant®) encompasses 83 countries in scope,for one cancer product, it provided evidence ofaffect the supply chain, works with several active

including 57 middle income countries. It has also

pricing and non-pricing strategies to ensure con-pharmaceutical ingredient suppliers, manages aissued a non-assert declaration for one patented

tinuous patient care while implementing healthbuffer stock of relevant products and is involved

compound in scope, darunavir (Prezista®).

systems strengthening initiatives. Johnson &in supply chain capacity building initiatives.

Johnson provides evidence of patient reach.
Filed to register new products in 15 countries in

Has a procedure for reporting substandard andscope on average. Johnson & Johnson has filed

Four of the five manufacturing capacity build-falsified (SF) medicines in countries in scope

filed six products in at least one country in scopeing initiatives included meet all Good Practiceof the Index in less than ten days. Johnson &of the Index with the highest burden of disease

Standards. Johnson & Johnson's performance

Johnson has a procedure for reporting SF med-(for products that could be assessed with availa-

is above average in this area. The number of ini-

icines to national health authorities within fiveble global burden of disease data, which excludes

tiatives meeting all inclusion criteria is higher

days. The company reports aiming at report-

COVID-19). Among new products, its most widely

than average and more initiatives meet all Gooding within two days if the case presents a direct

filed is the Johnson & Johnson COVID-19 vac-

Practice Standards (GPS) than what is averageand serious or life-threatening risk to patient orcine, rapidly authorized in 41 countries withinfor this indicator. For example, the company col-healthcare professional. It distinguishes quicker

the scope of the Index, 13 of which are LICs.

laborated with Aspen Pharmacare Limited, areporting time frames for cases which only

Examples include Somalia, Sudan and Uganda.

manufacturer in South Africa to transfer tech-require visual inspection to be confirmed.

Johnson & Johnson also received emergency use

nology to produce the Johnson & Johnson

waivers or import permits in 31 countries in scope

COVID-19 vaccine. This initiative meets all GPS.

metformin (Vokanamet®/Invokamet®) has been

All five supply chain capacity building initi-

lic policies and supply processes in place tofiled in 18 countries within the scope of the Index,

atives included for analysis meet all Good

ensure ad hoc donations are carried out rapidly inincluding one high burden disease country.

Practice Standards. Johnson & Johnson is one

response to expressed need, and it monitors theof the leaders in this area. The number of initia-delivery of donations.

Has access strategies for all supranationally

tives meeting all inclusion criteria is higher thanprocured products in scope for this analysis.

average and more initiatives meet all GPS thanPublicly commits to the achievement of elim-

Johnson & Johnson leads in securing access forwhat is average for this indicator. For example,

ination, eradication or control goals in one

products procured supranationally. For the four

the company is involved in the Strategic Training

structured donation programme for neglected

products assessed in this category, the company

Executives Programme (STEP 2.0) which is atropical diseases or malaria. Johnson & Johnson

demonstrates strategies both in countries eligi-

targeted leadership and change management

publicly commits to supporting the control of

ble for supply from such procurers, and also in

solution that trains public health supply chainsoil-transmitted helminthiasis as a public healthat least one country not eligible for such supply.

managers and leaders in LMICs.

problem through its donation of mebendazole

For example, the company supplied its Johnson

48

Donates in response to expressed need andmonitors delivery. Johnson & Johnson has pub-of the Index. Among old products, canagliflozin/(Vermox®) until the end of 2025 in 51 countries in& Johnson COVID-19 vaccine at a not-for-profit

All five health systems strengthening initiatives

price via a supranational procurement agreement

included for analysis meet all Good Practicescope of the Index.